Literature DB >> 10193387

Telomerase activity in human pleural mesothelioma.

K Dhaene1, R Hübner, S Kumar-Singh, B Weyn, E Van Marck.   

Abstract

BACKGROUND: Gradual telomere erosion eventually limits the replicative life span of somatic cells and is regarded as an ultimate tumour suppressor mechanism, eliminating cells that have accumulated genetic alterations. Telomerase, which has been found in over 85% of human cancers, elongates telomeres and may be required for tumorigenesis by the process of immortalisation. Malignant mesothelioma is an incurable malignancy with a poor prognosis. The disease becomes symptomatic decades after exposure to carcinogenic asbestos fibres, suggesting the long term survival of pre-malignant cell clones. This study investigated the presence of telomerase in pleural malignant mesothelioma, which may be the target for future anti-telomerase drugs.
METHODS: Telomerase activity was semiquantitatively measured in extracts from 22 primary pleural mesotheliomas, two benign solitary fibrous tumours of the pleura, four mesothelioma cell lines, and six short term mesothelial cell cultures from normal pleura using a non-isotopic dilution assay of the telomeric repeat amplification protocol.
RESULTS: Twenty of the 22 primary mesotheliomas (91%) and all tumour derived mesothelioma cell lines were telomerase positive. Different levels of enzyme activity were observed in the tumours of different histological subtypes. Telomerase activity could not be detected in the six normal mesothelial cell cultures or in the two mesotheliomas. Both benign solitary fibrous tumours showed strong telomerase activity.
CONCLUSIONS: Telomerase activity is found in a high proportion of mesotheliomas and anti-telomerase drugs might therefore be useful clinically. The results are consistent with the hypothesis that telomerase activity may be a feature of carcinogenesis in mesotheliomas and possibly in many other cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10193387      PMCID: PMC1745102          DOI: 10.1136/thx.53.11.915

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  Extension of life-span by introduction of telomerase into normal human cells.

Authors:  A G Bodnar; M Ouellette; M Frolkis; S E Holt; C P Chiu; G B Morin; C B Harley; J W Shay; S Lichtsteiner; W E Wright
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

Review 2.  Is telomerase activity in cancer due to selection of stem cells and differentiation arrest?

Authors:  M Greaves
Journal:  Trends Genet       Date:  1996-04       Impact factor: 11.639

Review 3.  The reactivation of telomerase activity in cancer progression.

Authors:  J W Shay; W E Wright
Journal:  Trends Genet       Date:  1996-04       Impact factor: 11.639

4.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP).

Authors:  N W Kim; F Wu
Journal:  Nucleic Acids Res       Date:  1997-07-01       Impact factor: 16.971

Review 5.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

6.  Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.

Authors:  C B Umbricht; M Saji; W H Westra; R Udelsman; M A Zeiger; S Sukumar
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

Review 7.  Telomere structure and telomerase expression during mouse development and tumorigenesis.

Authors:  D Kipling
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

8.  WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.

Authors:  S Kumar-Singh; K Segers; U Rodeck; H Backhovens; J Bogers; J Weyler; C Van Broeckhoven; E Van Marck
Journal:  J Pathol       Date:  1997-01       Impact factor: 7.996

9.  Telomerase activity in gynecological tumors.

Authors:  S Kyo; T Kanaya; H Ishikawa; H Ueno; M Inoue
Journal:  Clin Cancer Res       Date:  1996-12       Impact factor: 12.531

10.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity.

Authors:  C M Counter; A A Avilion; C E LeFeuvre; N G Stewart; C W Greider; C B Harley; S Bacchetti
Journal:  EMBO J       Date:  1992-05       Impact factor: 11.598

View more
  5 in total

1.  Telomerase activity in pleural malignant mesotheliomas.

Authors:  Amy Y M Au; Torben Hackl; Thomas R Yeager; Scott B Cohen; Harvey I Pass; Curtis C Harris; Roger R Reddel
Journal:  Lung Cancer       Date:  2011-01-31       Impact factor: 5.705

2.  NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Authors:  Vilde Drageset Haakensen; Anna K Nowak; Espen Basmo Ellingsen; Saima Jamil Farooqi; Maria Moksnes Bjaanæs; Henrik Horndalsveen; Tine Mcculloch; Oscar Grundberg; Susana M Cedres; Åslaug Helland
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

3.  Absence of telomerase activity and telemorase catalytic subunit mRNA in melanocyte cultures.

Authors:  K Dhaene; G Vancoillie; J Lambert; J M Naeyaert; E Van Marck
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

4.  Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Authors:  Brent D Kerger; Robert C James; David A Galbraith
Journal:  Front Genet       Date:  2014-05-30       Impact factor: 4.599

Review 5.  Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.

Authors:  Bhairavi Tolani; Luis A Acevedo; Ngoc T Hoang; Biao He
Journal:  Int J Mol Sci       Date:  2018-01-13       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.